

The impact of Hypertension in Progression of Chronic Renal Failure

S. Plješa

Nephrological Department of Internal Clinic, Clinical Hospital Zemun-Belgrade

Arterial hypertension (HTA), the most common noninfectious disease of modern world, which exists in 10-25% of world population, represents a big challenge for investigators and doctors for a while now. The explanation for this interest is based on fact that HTA complications are multiple and multiorganic, among which kidney has an important role. It is known that hypertensive nephrosclerosis (HN), as a direct complication of HTA in kidneys in 25% of cases leads to end stage renal disease in USA and in 8% of cases in Europe. For the reasons mentioned, a great attention of researchers is directed to examining and explaining the relation between hypertension and kidneys.

Many studies have shown that it takes more years of hypertensive status before the fixed proteinuria appears as the first sign of kidney damage, followed by renal failure without any other primary kidney disease. Chronic renal failure caused by hypertensive nephroangiosclerosis most often appears around age of 65 years, while it is very rare in younger people around age of 45 years. This indicates that apart from present hypertension, age is of great importance in appearance of HN. The incidence of patients with mild arterial hypertension is 1:6000 patients in Europe and 1:2200 in USA.

Hypertensive nephrosclerosis, as a direct complication of HTA in kidneys, in great percentage leads to end stage renal disease. The concept of glomerular ischemia is widely accepted as a primary lesion in HN, while many things are mentioned as other possible causes, such as genome which contributes in renal susceptibility for CRF, gene polymorphism which includes paracrine and autocrine agents which affect the endothelial and smooth muscle cells response to increased pressure and flow in afferent arterioli and their deranged response to increased Na^+ reach to macula densa. It is considered that apart from histological damages which are characteristic for HN there are some other, such as myointimal hyperplasia of interlobular and afferent arterioli and hyaline arteriosclerosis especially in afferent arterioli (1). These changes are a consequence of glomerular ischemia caused by shrinking of afferent arterioli. Shrinking of afferent arterioli leads to increased flow through the afferent arterioli causing extra myogenic contractile response which is followed by tubuloglomerular feedback from macula densa which autoregulates glomerular capillary pressure and flow under physiological conditions. Destruction of nephrons within CRF causes a loss in autoregulatory ability and transfer of systemic pressure to glomeruli, just as same

as puls increase of glomerular volume during each heart beat.

It is supposed that changes in afferent arterioli such as collapse of basal membrane caused by shrinking and global sclerosis may be expected within excessive contraction of afferent arterioli that is followed by a great reduction of glomerular blood flow and pressure. There are more and more data about endothelial cells demanding normal physiological level of shear stress caused by blood flow in order to avoid release of vasoconstrictors such as angiotensin II and endothelin in order to remain normal production of nitric oxide as vasodilator. Low shear stress may increase susceptibility of endothelial cells to damage, may prevent apoptosis and lower response to cytokines.(2) Decreased blood flow through the afferent arterioli leads to intrarenal activation of renin-angiotensin-aldosterone system that leads to stimulation of cytokine TGF- β production that activates fibrosis processes.


High intake of salt is not only pathogenetic factor for essential hypertension but can also cause renal fibrosis through increased production of TGF- β apart from its effect(3). Accordingly, excessive vasoconstriction most probably cause not only sodium retention and essential HTA but also contribute to development of HN.

There is a need for identification of patients who will develop terminal CRF, possibly in reversible phase, out of large number of those with essential HTA. Potential predictors are black race, elderly patients, positive family anamnesis for terminal CRF and avert microalbuminuria. It is shown that microalbuminuria significantly correlate with cardiovascular risk factors such as left ventricular hypertrophy, hyperlipidemia, increased pressure during night and increased diastolic blood pressure (4). Although we can not say how microalbuminuria represent early HTA effect on glomeruli and kidney function correlation of microalbuminuria with cardiovascular risk factors leads to intensive HTA therapy and blood pressure normalisation. It is possible that microalbuminuria represent indicator of early changes in secondary focal glomerulosclerosis especially if microalbuminuria show tendency of increasing.

It is evident that proteinuria represent the main pathophysiological mechanism of kidney damage in arterial hypertension. Proteinuria leads to glomerular and tubular damage causing nephron destruction which result in appearance of CRF (scheme 1).

If concept of primary glomerular ischemia is correct, logical conclusion may be that calcium antagonists could be anti

Scheme 1. Pathophysiology of kidney damage in arterial hypertension



hypertensives of first choice in HN treatment considering their ability to dilate afferent glomerular arteriola (5). Regulation of normal blood pressure is very important because it prevents transmission of systemic pressure to glomerular capillary circulation.

In the last period combined usage of calcium antagonists and ACE inhibitors is considered as a very reasonable solution. Calcium antagonists dilate afferent arteriola while ACE inhibitors inhibit and very efficiently prevent fibrosis and remodeling of preglomerular microvasculature (6).

Other therapeutic procedures such as usage of AT-2 receptor blockers and gene therapy are possible. Data about first experiments with gene therapy in HTA and HN are very interesting. They led to fascinating results of calcicreïn and NO gene usage in experimental animals (7). How will the growing knowledge in area of genetics and positive and negative effect of gene therapy be applied is still to be seen in new millennium.

References

1. Kashgarian M. Hypertensive Disease and kidney Structure. In: Laragh JH and Brenner BM eds. Hypertension: Pathophysiology, Diagnosis and Management, Second Edition, Raven Press, Ltd., New York: 1995:433-443.

2. Braddock M, Schwachtgen JL, Houston P, Dickson MC, Lee MJ, Campbell CJ. Fluid shear stress modulation of gene expression in endothelial cells. *News Physiol Sci* 1998; 13: 241-246.

3. Ying W, Sanders PW. Dietary salt modulates renal production of transforming-growth factor-β in rats. *Am J Physiol* 1998; 274 (Renal Physiol, 43): F635-F641

4. Pontremoli R, Viazi F, Sofa A et al. Microalbuminuria: A marker of cardiovascular risk and organ damage in essential hypertension. *Kidney Int* 1997; 52(Suppl): S163-S165.

5. Mene P. Calcium channel blockers: what they can and what they can't do. *Nephrol Dial Transpl* 1997; 12: 25-28.

6. Skov K, Fenger-Gron J, Mulvany MJ. Effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist, and an endothelin receptor antagonist on renal afferent arteriolar structure. *Hypertension* 1996; 28: 464-471.

7. Lin KF, Chao L, Chao J. Prolonged reduction of high blood pressure with human nitric oxide synthase gene delivery. *Hypertension* 1997; 30(I): 307-313